[HTML][HTML] Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
Haematologica, 2016•ncbi.nlm.nih.gov
7 IDH1 4 with IDH1 11 IDH1 11 IDH2 4 with IDH2 15 IDH2 TET2 mutants 14 4 18 NPM1
mutants 7 1 8 FLT3 mutants 4 with FLT3-ITD 2 with FLT3-ITD 6 with FLT3-ITD 2 with FLT3-
TKDb 2 with FLT3-TKDb 4 with FLT3-TKDb 3 were not tested 3 were not tested NGS
performed at time of initial AML diagnosis 53% 81% 60% NGS performed prior to HMA
initiation 68% 76% 70%% Females 37% 57% 42% Median age 66 73 70 Median WBC
count 5.8 2.5 3.2 Median hemoglobin 9.1 9.2 9.1 Median platelet count 80 64 71 Median …
mutants 7 1 8 FLT3 mutants 4 with FLT3-ITD 2 with FLT3-ITD 6 with FLT3-ITD 2 with FLT3-
TKDb 2 with FLT3-TKDb 4 with FLT3-TKDb 3 were not tested 3 were not tested NGS
performed at time of initial AML diagnosis 53% 81% 60% NGS performed prior to HMA
initiation 68% 76% 70%% Females 37% 57% 42% Median age 66 73 70 Median WBC
count 5.8 2.5 3.2 Median hemoglobin 9.1 9.2 9.1 Median platelet count 80 64 71 Median …
7 IDH1 4 with IDH1 11 IDH1 11 IDH2 4 with IDH2 15 IDH2 TET2 mutants 14 4 18 NPM1 mutants 7 1 8 FLT3 mutants 4 with FLT3-ITD 2 with FLT3-ITD 6 with FLT3-ITD 2 with FLT3-TKDb 2 with FLT3-TKDb 4 with FLT3-TKDb 3 were not tested 3 were not tested NGS performed at time of initial AML diagnosis 53% 81% 60% NGS performed prior to HMA initiation 68% 76% 70%% Females 37% 57% 42%
Median age 66 73 70 Median WBC count 5.8 2.5 3.2 Median hemoglobin 9.1 9.2 9.1 Median platelet count 80 64 71 Median bone marrow blast% 42 40 40 Cytogenetic risk 37%(22/59) with poor-risk 30%(7/21) with poor-risk 36%(29/80) poor-risk by NCCN by NCCN by NCCN
ncbi.nlm.nih.gov
